Elevation Oncology (NASDAQ: ELEV) has filed to IPO 6.25M shares at $15-$17 per share.
ELEV is a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. It is focused on identifying oncogenic drivers that are known to be predominantly mutually exclusive with other driver alterations and pursuing innovations and efficiencies in the conduct of clinical trials that they believe may enable development of targeted therapeutics against those oncogenic drivers.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.